CSBR vs. VECT, OPT, VALN, RLAY, RGNX, CGEM, MAZE, SANA, MGTX, and AUTL
Should you be buying Champions Oncology stock or one of its competitors? The main competitors of Champions Oncology include VectivBio (VECT), Opthea (OPT), Valneva (VALN), Relay Therapeutics (RLAY), REGENXBIO (RGNX), Cullinan Therapeutics (CGEM), Maze Therapeutics (MAZE), Sana Biotechnology (SANA), MeiraGTx (MGTX), and Autolus Therapeutics (AUTL). These companies are all part of the "biological products, except diagnostic" industry.
Champions Oncology vs.
Champions Oncology (NASDAQ:CSBR) and VectivBio (NASDAQ:VECT) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, valuation, earnings, profitability, community ranking, analyst recommendations, dividends, institutional ownership and media sentiment.
In the previous week, Champions Oncology had 8 more articles in the media than VectivBio. MarketBeat recorded 8 mentions for Champions Oncology and 0 mentions for VectivBio. Champions Oncology's average media sentiment score of 1.04 beat VectivBio's score of 0.00 indicating that Champions Oncology is being referred to more favorably in the media.
41.3% of Champions Oncology shares are held by institutional investors. 47.0% of Champions Oncology shares are held by insiders. Comparatively, 9.7% of VectivBio shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
VectivBio has a net margin of 0.00% compared to Champions Oncology's net margin of -1.12%.
Champions Oncology has higher revenue and earnings than VectivBio.
Champions Oncology currently has a consensus price target of $12.00, indicating a potential upside of 106.19%. Given Champions Oncology's stronger consensus rating and higher probable upside, equities analysts clearly believe Champions Oncology is more favorable than VectivBio.
Champions Oncology received 142 more outperform votes than VectivBio when rated by MarketBeat users. Likewise, 60.56% of users gave Champions Oncology an outperform vote while only 43.48% of users gave VectivBio an outperform vote.
Champions Oncology has a beta of 0.28, indicating that its stock price is 72% less volatile than the S&P 500. Comparatively, VectivBio has a beta of 0.11, indicating that its stock price is 89% less volatile than the S&P 500.
Summary
Champions Oncology beats VectivBio on 12 of the 15 factors compared between the two stocks.
Get Champions Oncology News Delivered to You Automatically
Sign up to receive the latest news and ratings for CSBR and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Champions Oncology Competitors List
Related Companies and Tools
This page (NASDAQ:CSBR) was last updated on 6/2/2025 by MarketBeat.com Staff
Buy CSBR Stock Free CSBR Stock Alerts